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The aim of this first study was to reveal the new potential biomarkers by a metabolomics approach in severe septic calves. Sepsis is a
common cause of morbidity and mortality in newborn dairy calves. The main challenges with the use of biomarkers of sepsis in
domestic animals are their availability, cost, and time required to obtain a result. Metabolomics may offer the potential to
identify biomarkers that define calf sepsis in terms of combined clinical, physiological, and pathobiological abnormalities. To
our knowledge, this is the first study presenting an NMR- (nuclear magnetic resonance-) based plasma metabolomics at set
intervals in neonatal septic calves. Twenty neonatal dairy calves with severe sepsis and ten healthy calves were used.
Hematological and biochemical health profiles were gathered in plasma samples at set intervals. Similarly, NMR spectra were
acquired. All diseased animals (except one) died after 72 hours. Clinical and laboratory results were in accordance with those of
severe septic animals. Multivariate analysis on NMR plasma spectra proved to be an excellent tool for faster identification of
calves with severe sepsis from healthy animals. The NMR-based metabolomic profile may contribute to the better understanding
of severe sepsis in newborn calves.
1. Introduction
The mortality risk of live-born newborn calves, 1 month of
age, has been reported to range from 15 to 30%. The majority
of deaths are attributable to infectious diseases; diarrhea,
pneumonia, and sepsis are the most common. Sepsis is an
acute systemic inflammatory response of the body to micro-
bial infection and a life-threatening condition associated with
multiple-organ failure [1]. Newborn sepsis is the third most
common cause of calf mortality in the United States (behind
diarrhea and respiratory disease) and occurs most commonly
in calves associated with failure of passive transfer. The early
signs of sepsis in newborn calves are vague and nonspecific
and are often indistinguishable from signs of noninfectious
diseases or those of focal infections such as diarrhea. Positive
blood cultures are required for a definitive antemortem
diagnosis of sepsis, but results are not reported for 48–72
hours, and false-negative culture findings are common. The
high mortality of sepsis can be seen as an indication of insuf-
ficient laboratory diagnostics [2]. Unfortunately, despite
many advances, the majority of laboratory investigations
are not sufficiently sepsis specific. The laboratory diagnosis
of sepsis is thus a mosaic of different technological and meth-
odological approaches which are vital to the subsequent inte-
gration of the clinical picture and outcome of the septic
patient [3]. Fortunately, the advent of “omic” technologies
may allow for increased diagnostic support. The metabolo-
mics approach offers the possibility to identify variations in
fingerprint and metabolite profile that can be used to dis-
criminate disease [4]. Metabolomics may become a promis-
ing tool for diagnosing newborn sepsis and monitoring
therapy in the near future. Taking into consideration the
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studies carried out so far, it is reasonable to argue that the
metabolomics technique can be considered an effective tool
for the diagnosis of sepsis [5, 6]. While metabolomic stud-
ies are often encountered in human medicine for newborn
sepsis [7–14], there is little knowledge related to the same
approach for calf sepsis. The aim of the present study was
to identify metabolomic biomarkers of sepsis in plasma
by 1H-NMR spectroscopy to assess the severity and to pre-
dict outcomes.
2. Materials and Methods
2.1. Animals and Sepsis Criteria. Twenty newborn calves
presented for treatment to the teaching hospital, 1–15 days
of age with severe sepsis, and 10 clinically healthy age-
matched control calves belonging to the faculty farm were
used in this study. Inclusion criteria were the following: SIRS
(systemic inflammatory response syndrome) criteria: body
temperature> 39°C or <36°C, hearth rate< 100 or >160
beats/min, respiratory rate> 65/min or pCO2> 50mmHg,
total leukocyte count> 12.000/mm3 or <4.000/mm3, or band
neutrophil> 10%; sepsis criteria: at least two results above or
more than SIRS+ infection or infection suspected; and severe
sepsis criteria: 4 sepsis results together with at least one organ
failure (acute lung damage; coagulation abnormalities;
thrombocytopenia; mental state changes; and liver, kidney,
or/and cardiac insufficiency or acidosis due to hypoperfu-
sion) [15].
2.2. Blood Sampling. Diseased calves were treated by antibi-
otics and fluids, and critical care was performed, when
needed. Their blood samples were taken at set intervals (0,
3, 6, 12, 48, and 72 h) after admission to the animal hospital,
and serum and plasma samples were harvested by centrifug-
ing the blood at 1000×g for 15min at 4°C.
2.3. Laboratory Analysis. Laboratory workup including com-
plete blood count analysis (blood cell counts, hematocrit,
hemoglobin, MCV, MCH, and MCHC), blood gas analysis
(pH, pO2, pCO2, HCO3, base excess, and O2 saturation),
and biochemical analyses (in serum samples: total protein,
albumin, BUN, creatinine, lactate, AST, ALT, ALP, GGT,
Na, and K) was performed by use of automated analyzers
in the teaching hospital’s clinical laboratory.
2.4. 1H-NMR Sample Preparation. NMR measurements were
performed at the CERM/CIRMMP center of the ESFRI
Instruct, University of Florence, in Florence, Italy. 350μL of
each plasma sample was added to a total of 350μL of a phos-
phate sodium buffer (70mM Na2HPO4; 20% (v/v)
2H2O;
0.025% (v/v) NaN3; 0.8% (w/v) sodium trimethylsilyl
[2,2,3,3-2H4] propionate (TMSP), pH7.4), and the mixture
was homogenized by vortexing for 30 s. A total of 600μL of
this mixture was transferred into a 5mm NMR tube (Bruker
BioSpin s.r.l.) for the analysis.
2.5. NMR Analysis. Monodimensional 1H-NMR spectra for
all samples were acquired using a Bruker 600MHz spectrom-
eter (Bruker BioSpin s.r.l.; Rheinstetten, Germany) operating
at 600.13MHz proton Larmor frequency and equipped with
a 5mm PATXI 1H-13C-15N and 2H decoupling probe
including a z-axis gradient coil, an automatic tuning and
matching (ATM), and an automatic and refrigerated sample
changer (SampleJet, Bruker BioSpin s.r.l.; Rheinstetten,
Germany). A BTO 2000 thermocouple was served for tem-
perature stabilization at the level of approximately 0.1K at
the sample. Before measurement, samples were kept for at
least 5 minutes inside the NMR probehead, for temperature
equilibration (310K for plasma samples).
For each sample, three one-dimensional proton NMR
spectra were acquired with different pulse sequences, allow-
ing the selective detection of different molecular compo-
nents [16].
(i) A standard nuclear Overhauser effect spectroscopy
pulse sequence NOESY 1Dpresat (noesygppr1d.-
comp; Bruker BioSpin) pulse sequence, using 32
scans, 98,304 data points, a spectral width of
30.0459Hz, an acquisition time of 2.7 s, a relaxation
delay of 4 s, and a mixing time of 0.1 s, and with
water peak suppression [17], was applied to obtain
a spectrum which are visible signals of metabolites
and high molecular weight macromolecules (lipids
and lipoproteins).
(ii) A standard spin echo Carr-Purcell-Meiboom-Gill
(CPMG) [18] (cpmgpr1d.comp; Bruker BioSpin)
pulse sequence applied to a standard 1D sequence,
with 32 scans, 73,728 data points, a spectral width
of 12,019Hz, and a relaxation delay of 4 s, was
used for the selective observation of low molecu-
lar weight metabolites, suppressing signals arising
from macromolecules.
(iii) A standard diffusion-edited [19] (ledbgppr2s1d.-
comp; Bruker BioSpin) pulse sequence, using 32
scans, 98,304 data points, a spectral width of
18,028Hz, and a relaxation delay of 4 s, was applied
to suppress metabolite signals.
The acquisition conditions used in this work are perfectly
in line with what is validated and recommended in literature
[20]. These conditions are suggested by Bruker (the NMR
machine vendor) for metabolomic analysis [21].
2.6. Spectral Processing. Free induction decays were multi-
plied by an exponential function equivalent to a 0.3Hz line-
broadening factor before applying Fourier transform.
Transformed spectra were automatically corrected for
phase and baseline distortions and calibrated to anomeric
glucose doublet at 5.24 ppm using TopSpin 3.2 (Bruker
BioSpin s.r.l.).
Each 1D spectrum in the range between 0.2 and
10.00 ppm was segmented into 0.02 ppm chemical shift bins,
and the corresponding spectral areas were integrated using
AMIX software (version 3.8.4, Bruker BioSpin). Binning is
a means to reduce numbers of total variables and to compen-
sate for small shifts in the signals, making the analysis more
robust and reproducible [22]. Regions containing residual
water signal were removed.
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2.7. Statistical Analysis. For laboratory data, normality test
was performed to explain if all data are parametric or non-
parametric. For comparing the parametric values, ANOVA
and Tukey tests were performed and calculated as mean
± SD. For comparing the nonparametric ones, Mann–Whit-
ney U test was performed and presented as median (SPSS
21.0). Statistical significance was evaluated as P value< 0.05.
Principal component analysis (PCA) was used as a first
exploratory analysis. Orthogonal projections to latent struc-
tures (OPLS) was chosen as supervised technique. OPLS is
a multivariate projection method which is frequently applied
for modelling spectroscopic data. This algorithm is able to
separate “response-related” and “response-orthogonal” vari-
ation in data, providing benefits in terms of model interpre-
tation compared to PCA or to PLS [23]. All the accuracies
reported and the confusion matrix for different classifications
were assessed by means of 100 cycles of a Monte Carlo cross-
validation scheme (MCCV, R script in-house developed). In
this case, 90% of the data were randomly chosen at each iter-
ation as a training set to build the model. Then the remaining
10% was tested and sensitivity, specificity, and accuracy for
the classification were assessed. The procedure was repeated
100 times to derive an average discrimination accuracy for
each group of subjects.
For metabolomic data, twenty-two metabolites, corre-
sponding to well-defined and resolved peaks in the spectra,
were assigned. Signal identification was performed using a
library of NMR spectra of pure organic compounds, public
databases (e.g., HMBD), and literature data.
The molecule 1,4-dioxane was used as reference standard
to perform a quantitative NMR (qNMR) analysis on the
plasma samples to obtain absolute concentration (μM) values
of the metabolites analyzed. The concentrations of the vari-
ous metabolites in the different spectra were calculated by
spectral fitting and integration of the signal area using in-
house MATLAB® scripts and the concentrations of peak
integrals are compared to the internal standard peak integral
to obtain absolute concentrations, using cpmg spectra. The
use of CPMG spectra for quantitative analysis is well sup-
ported by literature [24]. Kruskal-Wallis test followed by
Dunn post hoc analysis was chosen to infer metabolite differ-
ences among the groups on the biological assumption that
metabolite concentrations are not normally distributed. False
discovery rate correction was applied using the Benjamini-
Hochberg method (FDR) and adjusted P value< 0.05 was
considered statistically significant [25]. MetaboAnalyst 3.0
was used for pathway analysis [26].
3. Results
3.1. Clinical and Laboratory Data. The diseased calves
were recumbent, weak, dehydrated (≥8%), and hypothermic
(T = 36 8°C). Poor pulse quality and occasional pulse deficits
were revealed by palpation and auscultation, and heart rate
(92 beats/min) was within normal limits except two animals
in which atrial standstill was observed. The animals had
metabolic acidosis, hyperkalemia, lactatemia, and leukocy-
tosis. O2 saturation remained decreased, and BUN, creati-
nine, and AST increased at set intervals in spite of therapy
(Supplemental Tables 1, 2 and 3). Three animals died at
the 24th hour and at the 48th hour, and two animals at
the 72nd hour. The remaining animals (11) died after the
72nd hour.
3.2. NMR-Based Metabolites. NMR spectra of all 113 plasma
samples were acquired, sample n°15 (0 h) was removed from
our analysis because the spectrum was of bad quality. Proc-
essed plasma samples of newborn calves, collected at differ-
ent time points (Healthy animals (Ha); diseased animals at 0
hour; diseased animals at the 3rd hour; diseased animals at
the 6th hour; diseased animals at the 24th hour; diseased
animals at the 48th hour; and diseased animals at the
72nd hour), have been analyzed firstly using the unsuper-
vised multivariate method (PCA) to gain an overview on
the main changes responsible for sepsis. Figure 1 shows
the PCA score plots on 1D NOESY, CPMG, and diffusion-
edited spectra of plasma samples. Unsupervised principal
component analysis of all plasma spectra is sufficient to dis-
criminate, in all the three experiments, healthy animals (Ha,
yellow dots) from calves with sepsis, and particularly 0 h
blood samples (brown dots) can be distinguished from the
other time points, suggesting that from the 3rd to the
72nd hour, plasma profile/metabolism of newborn calves
with sepsis is very similar.
Subsequently, the OPLS-supervisedmethod was employed
to extract and visualize latent and hidden variation character-
istics of sepsis progression. OPLS models were built on
NOESY, CPMG, and diffusion-edited experiments, respec-
tively (Figures 2(a)–2(c)) and the first 10 components were
retained in the model. All the three models, as shown by
cross-validations (Figure 2), are able to excellently identify
healthy animals (Ha) with 90% and 100% accuracy using
OPLS models built on NOESY and CPMG experiments,
respectively. Interestingly, 0 h plasma samples appear the
most discriminated, while from the 3rd hour to the 72nd
hour, each group cannot be recognized with good accuracy.
Using the same statistical approach, discrimination analysis
was also attempted to check whether the metabolic profile
at time 0 differed between animals that died early from those
that died later to check if the metabolic profile can predict
animal outcome before starting the therapeutic treatment.
However, the predictive accuracies obtained from the models
were very low (predictive accuracy on the NOESY model:
39%, predictive accuracy on the CPMGmodel: 44%, and pre-
dictive accuracy on the diffusion-edited model: 38%); this
unsatisfactory result can be ascribed to the fact that the num-
ber of samples per group is too low or also because all animals
(except one) died after 72 hours leading to the conclusion
that all individuals share the same pathological fingerprint.
NMR spectra were also analyzed to identify which
metabolites are altered in the seven groups of calves. The
twenty-two identified and quantified metabolites are listed
in Table 1; P values are reported only for metabolites that
differ significantly (P value< 0.05) (Figure 3). Diseased
samples at 0 hour compared with healthy animals appeared
to be richer in isoleucine, leucine, valine, alanine, creatine,
phosphocreatine, glycine, phenylalanine, and histidine which
decreased gradually along hours. Allantoin, 3-hydroxybutyric
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Figure 1: Principal component analysis (PCA) score plots. Each dot represents a single NMR spectrum of plasma samples collected at
different time points: healthy animals (Ha, yellow dots), 0 hour (brown dots), 3rd hour (green dots), 6th hour (magenta dots), 24th hour
(light-blue dots), 48th hour (gray dots), and 72nd hour (red dots). (a) PCA on all 1D NOESY spectra; (b) PCA on Ha, 0 h, and 3rd-hour
1D NOESY spectra; (c) PCA on all CPMG spectra; (d) PCA on Ha, 0 h, and 3rd-hour CPMG spectra; (e) PCA on all diffusion-edited
spectra; (f) PCA on Ha, 0 h, and 3rd-hour diffusion-edited spectra.
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OPLS ON 1D NOESY
Ha 0 h 3 h 6 h 24 h 48 h 72 h
Ha 90 0 0 0 0 0 10
0 h 0 68.4 10.5 10.5 5.3 0 5.3
3 h 0 5 50 45 0 0 0
6 h 0 5 30 35 25 0 5
24 h 0 0 5.9 35.3 17.6 35.3 5.9
48 h 7.1 0 0 0 28.6 7.1 57.1
72 h 0 0 0 8.3 16.7 58.3 16.7
Confusion matrix:
Predictive accuracy: 40.2%
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OPLS ON CPMG
Ha 0 h 3 h 6 h 24 h 48 h 72 h
Ha 100 0 0 0 0 0 0
0 h 0 57.9 15.8 10.5 5.3 5.3 5.3
3 h 0 5 30 50 10 0 5
6 h 5 5 25 50 15 0 0
24 h 0 0 5.9 35.3 11.8 29.4 17.6
48 h 0 0 7.1 0 42.9 14.3 35.7
72 h 0 0 0 0 16.7 66.7 16.7
Confusion matrix:
Predictive accuracy: 38.4%
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OPLS on diffusion edited
Ha 0 h 3 h 6 h 24 h 48 h 72 h
Ha 70 0 0 20 0 10 0
0 h 0 47.4 21.1 10.5 10.5 5.3 5.3
3 h 0 0 40 45 10 5 0
6 h 0 5 40 25 25 0 5
24 h 0 17.6 0 41.2 17.6 17.6 5.9
48 h 0 0 0 7.1 35.7 14.3 42.9
72 h 0 0 0 16.7 16.7 50 16.7
Confusion matrix:
Predictive accuracy: 32%
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Figure 2: OPLS score plot of all plasma samples: healthy animals (Ha, yellow dots), 0 hour (brown dots), 3rd hour (green dots), 6th hour
(magenta dots), 24th hour (light-blue dots), 48th hour (gray dots), and 72nd hour (red dots). (a) NOESY experiment; (b) CPMG
experiment; (c) diffusion-edited experiment. Confusion matrices and related prediction accuracy of cross-validation analyses are reported
for each model.
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acid, acetone, and isobutyric acid remained increased at all
thehours.While acetone gradually increased, choline andpro-
line gradually reduced along hours. Formic acid is decreased
at 0 hour then increased gradually.
4. Discussion
NMR-based metabolomics were evaluated at set intervals,
for the first time, in newborn calves with severe sepsis. The
data indicated that metabolomics was a feasible tool for the
identification of septic plasma profiles and quantification
of potential meaningful biomarkers for severe septic new-
born calves. Newborn sepsis commonly originates from an
abrupt evolution of infections in the first 4 weeks of life.
Clinical signs of newborn sepsis are often nonspecific, subtle,
and inconspicuous and therefore demand a high index of
suspicion for early diagnosis [2]. In this present study, clin-
ical and laboratory results at admission were in accordance
with most references. Clinical findings especially mental sta-
tus contrary to leukocytosis, metabolic acidosis, lactatemia,
and hyperkalemia could not be corrected properly. In the
diseased animals, O2 saturation remained decreased; how-
ever BUN, creatinine, and AST were increased along all
hours. All the animals (except one) died after 72 h. This
may be attributed to multiple-organ failure. These labora-
tory results on animal serum samples obtained by analytical
methods optimized for human matrix may be questionable,
even though they may be considered indicative.
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Figure 3: Box plots of the metabolites differentially concentrated in the seven calf groups. Ha: healthy animals; 0 h: diseased animals at 0 hour;
3 h: diseased animals at the 3rd hour; 6 h: diseased animals at the 6th hour; 24 h: diseased animals at the 24th hour; 48 h: diseased animals at
the 48th hour; 72 h: diseased animals at the 72nd hour.
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There are a variety of tests that are helpful for screening
newborns with sepsis. Traditional biomarkers do not suffi-
ciently discriminate between sepsis and SIRS. Thus, the iden-
tification of more sensitive reliable and rapidly measured
biomarkers to differentiate sepsis from SIRS andmonitor dis-
ease progression and treatment efficacy is a matter of intense
interest. This study has shown that NMR metabolomics
could represent an optimal tool for faster identification of
newborn calves with severe sepsis and a complementary tool
to classical methods used until now to stratify better the
prognosis in septic shock and severe sepsis. The usefulness
of metabolomics in exploring underlying biochemical mech-
anisms of sepsis could—after validation—provide novel can-
didate mechanisms to confirm or follow-up the progression
of newborn early- or late-onset sepsis [27, 28]. Urinary 1H-
NMR and GC-MS metabolomics predict early- and late-
onset newborn sepsis [8]. In the study, the variables signifi-
cantly contributing to the separation of the septic samples
from healthy animals in multivariate analysis included sev-
eral metabolites such as acetate, glycine, glucose, acetone, lac-
tate, and lysine, whereas control samples were characterized
by citrate and creatinine. In another 1H-NMR human study,
several metabolites (maltose, glucose, biotine, methylamine,
inosine, methylguanidine, creatine, myoinositol, and quinoli-
nic acid) were found significantly changed in septic neonates
at the onset of the disease [28]. In this current study, identi-
fied and quantified metabolites and their functions are the
following: valine: synthesis of glutamine and alanine and bal-
ance among branched-chain amino acid (BCAA); proline:
collagen structure and function, neurological function, and
osmoprotection; choline: synthesis of betaine, acetylcholine,
phosphatidylcholine, and sarcosine; alanine: inhibition of
pyruvate kinase and hepatic autophagy, gluconeogenesis,
transamination, and glucose-alanine cycle; phenylalanine:
activation of BH4 (a cofactor for NOS) synthesis, synthesis
of tyrosine, and neurological development and function; leu-
cine: regulation of protein turnover through cellular mecha-
nistic target of rapamycin signaling and gene expression,
activator of glutamate dehydrogenase, BCAA balance, and
flavor enhancer; isoleucine: synthesis of glutamine and ala-
nine and balance among BCAA; histidine: protein methyla-
tion, hemoglobin structure and function, antioxidative
dipeptides, and one-carbon unit metabolism; glycine: calcium
influx through a glycine-gated channel in the cell membrane,
purine and serine syntheses, synthesis of porphyrins, inhibi-
tory neurotransmitter in the central nervous system, and coa-
gonist with glutamate for N-methyl-D-aspartate receptors;
and creatine: antioxidant, antiviral, antitumor, energy metab-
olism in muscle and brain, and neurological and muscular
development and function [29]. Most metabolites increased
at 0 hour (Supplemental Table 1) indicated the response to
metabolic deficits for early-onset sepsis. These metabolites
gradually decreased at other hours following the therapy.
Also, the presence of ketone bodies such as acetone, 3-
hydroxybutyric acid, and isobutyric acid in the plasma of
the septic group at all hours suggests a compensatory
reaction to a reduced level of ATP [8]. A simplified list of
the most contributing metabolic pathways is reported in
Supplemental Table 4 based on MetaboAnalyst software.
The analysis showed alteration in biochemical pathways like
aminoacyl-tRNA biosynthesis (histidine, phenylalanine, gly-
cine, valine, alanine, isoleucine, leucine, and proline), valine/
leucine/isoleucine biosynthesis (pyruvate, leucine, valine, and
isoleucine), nitrogen metabolism (phenylalanine, histidine,
glycine, and formate), glycine/serine and threonine metabo-
lism (choline, glycine, creatine, and pyruvate), and synthesis
and degradation of ketone bodies (3-hydroxybutyrate, ace-
tone). The analysis was calculated based on the significance
value (P value< 0.05) of the pathway enrichment analysis.
In our previous study [30] where the measurements were
not at set intervals, the whole lipid soluble metabolites such
as sphingomyelin and fatty acids including PUFA were
reduced and attributed to a great systemic energy deficit dur-
ing sepsis. Being in accordance with Langley and Wong [31],
it is said that metabolomic changes in sepsis suggest an
energy crisis in nonsurvivors. Some metabolites such as for-
mic acid in this present study were similar to those in the pre-
vious study. Remarkable increased allantoin of the septic
group in this present study can be an indication of microbial
overgrowth or oxidative stress. Cell death from cytochrome
oxidase inhibition by formic acid believed to result partly
from depletion of ATP, reducing energy concentrations so
that essential cell functions cannot be maintained. In this
regard, gradually increasing of formic acid being decreased
at 0 hour can be meaningful for prognosis of septic calves.
5. Conclusions
To our knowledge, this is the first study where the measure-
ments were at set intervals showing that 1HNMR-basedmeta-
bolomics approach may indeed be a powerful instrument
providing knowledge about the factors responsible of the
metabolic modifications in newborn septic calves. NMR
metabolomics proved to be an optimal tool for faster identi-
fication of newborn calves with sepsis using plasma samples.
Although identified and quantified metabolites may become
potential biomarkers for diagnosing newborn sepsis and
monitoring therapy of sepsis in calves, the extent of the pre-
dictive and prognostic values of this given set of metabolites
will be required for clinical trials.
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